2026-04-18T17:16:42Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/164192024-09-21T11:09:30Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Venegas-Rodríguez, Ana author Pello, Ana María author López-Castillo, Marta author Taibo Urquía, Mikel author Balaguer-Germán, Jorge author Munté, Alicia author González-Martín, Guillermo author Carriazo-Julio, Sol María author Martínez-Milla, Juan author Kallmeyer, Andrea author González Lorenzo, Óscar author Gaebelt Slocker, Hans Paul author Tuñón, José author González-Parra, Emilio author Aceña, Álvaro author 2023-08 AIMS Residual congestion at the time of hospital discharge is an important readmission risk factor, and its detection with physical examination and usual diagnostic techniques have strong limitations in overweight and obese patients. New tools like bioelectrical impedance analysis (BIA) could help to determine when euvolaemia is reached. The aim of this study was to investigate the usefulness of BIA in management of heart failure (HF) in overweight and obese patients. METHODS AND RESULTS Our study is a single-centre, single-blind, randomized controlled trial that included 48 overweight and obese patients admitted for acute HF. The study population was randomized into two arms: BIA-guided group and standard care. Serum electrolytes, kidney function, and natriuretic peptides were followed up during their hospital stay and at 90 days after discharge. The primary endpoint was development of severe acute kidney injury (AKI) defined as an increase in serum creatinine by >0.5 mg/dL during hospitalization, and the main secondary endpoint was the reduction of N-terminal pro-brain natriuretic peptide (NT-proBNP) levels during hospitalization and within 90 days after discharge. The BIA-guided group showed a remarkable lower incidence of severe AKI, although no significant differences were found (41.4% vs. 16.7%; P = 0.057). The proportion of patients who achieved levels of NT-proBNP < 1000 pg/mL at 90 days was significantly higher in the BIA-guided group than in the standard group (58.8% vs. 25%; P = 0.049). No differences were observed in the incidence of adverse outcomes at 90 days. CONCLUSIONS Among overweight and obese patients with HF, BIA reduces NT-proBNP levels at 90 days compared with standard care. In addition, there is a trend towards lower incidence of AKI in the BIA-guided group. Although more studies are required, BIA could be a useful tool in decompensated HF management in overweight and obese patients. ESC Heart Fail. 2023 Aug;10(4):2418-2426. http://hdl.handle.net/20.500.12105/16419 37226407 10.1002/ehf2.14398 2055-5822 ESC heart failure The role of bioimpedance analysis in overweight and obese patients with acute heart failure: a pilot study.